GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lepu Biopharma Co Ltd (HKSE:02157) » Definitions » Retained Earnings

Lepu Biopharma Co (HKSE:02157) Retained Earnings : HK$-2,952.1 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Lepu Biopharma Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Lepu Biopharma Co's retained earnings for the quarter that ended in Dec. 2024 was HK$-2,952.1 Mil.

Lepu Biopharma Co's quarterly retained earnings declined from Dec. 2023 (HK$-2,574.3 Mil) to Jun. 2024 (HK$-2,740.9 Mil) and declined from Jun. 2024 (HK$-2,740.9 Mil) to Dec. 2024 (HK$-2,952.1 Mil).

Lepu Biopharma Co's annual retained earnings increased from Dec. 2022 (HK$-2,603.6 Mil) to Dec. 2023 (HK$-2,574.3 Mil) but then declined from Dec. 2023 (HK$-2,574.3 Mil) to Dec. 2024 (HK$-2,952.1 Mil).


Lepu Biopharma Co Retained Earnings Historical Data

The historical data trend for Lepu Biopharma Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lepu Biopharma Co Retained Earnings Chart

Lepu Biopharma Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
Get a 7-Day Free Trial -748.53 -2,011.11 -2,603.61 -2,574.30 -2,952.07

Lepu Biopharma Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,603.61 -2,705.35 -2,574.30 -2,740.90 -2,952.07

Lepu Biopharma Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Lepu Biopharma Co  (HKSE:02157) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Lepu Biopharma Co Business Description

Traded in Other Exchanges
N/A
Address
No. 651, Lianheng Road, Minhang District, Shanghai, CHN, 201612
Lepu Biopharma Co Ltd is a biopharmaceutical company focusing on oncology therapeutics and has one operating segment. The Group is principally engaged in the sales of pharmaceutical products and the research and development of new drugs. The majority operating entity of the Group is domiciled in the PRC. The company has established an integrated end-to-end platform across drug discovery, clinical development, CMC, and GMP-compliant manufacturing, encompassing all critical functions of the biopharmaceutical value chain.
Executives
Pu Zhongjie 2201 Interest of corporation controlled by you
Hu Chaohong 2201 Interest of corporation controlled by you
Pu Jue 2201 Interest of corporation controlled by you
Hao Chunmei 2202 Interest of your spouse
Su Rongyu 2101 Beneficial owner
Miracogen Inc. 2201 Interest of corporation controlled by you
Miracogen Limited 2101 Beneficial owner
Cereblue Limited 2201 Interest of corporation controlled by you
Bei Jing Hou De Yi Min Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Hou De Yi Min Xin Xi Ke Ji You Xian Gong Si 2101 Beneficial owner
Le Pu Bei Jing Yi Liao Qi Xie Gu Fen You Xian Gong Si 2101 Beneficial owner
Lv Yuan Shang Hai Ke Ji You Xian Gong Si 2101 Beneficial owner

Lepu Biopharma Co Headlines

No Headlines